Department of Radiology, University of California Davis Medical Center, Sacramento, CA 95817, USA.
Radiology. 2010 Sep;256(3):714-23. doi: 10.1148/radiol.10092311.
To quantify contrast material enhancement of breast lesions scanned with dedicated breast computed tomography (CT) and to compare their conspicuity with that at unenhanced breast CT and mammography.
Approval of the institutional review board and the Radiation Use Committee and written informed consent were obtained for this HIPAA-compliant study. Between September 2006 and April 2009, 46 women (mean age, 53.2 years; age range, 35-72 years) with Breast Imaging Reporting and Data System category 4 or 5 lesions underwent unenhanced breast CT and contrast material-enhanced breast CT before biopsy. Two radiologists independently scored lesion conspicuity for contrast-enhanced breast CT versus mammography and for contrast-enhanced breast CT versus unenhanced breast CT. Mean lesion voxel intensity was measured in Hounsfield units and normalized to adipose tissue intensity on manually segmented images obtained before and after administration of contrast material. Regression models focused on conspicuity and quantified enhancement were used to estimate the effect of pathologic diagnosis (benign vs malignant), lesion type (mass vs calcifications), breast density, and interradiologist variability.
Fifty-four lesions (25 benign, 29 malignant) in 46 subjects were analyzed. Malignant lesions were seen significantly better at contrast-enhanced breast CT than at unenhanced breast CT (P < .001) or mammography (P < .001). Malignant calcifications (malignant lesions manifested mammographically as microcalcifications only, n = 7) were seen better at contrast-enhanced breast CT than at unenhanced breast CT (P < .001) and were seen similarly at contrast-enhanced breast CT and mammography. Malignant lesions enhanced 55.9 HU +/- 4.0 (standard error), whereas benign lesions enhanced 17.6 HU +/- 6.1 (P < .001). Ductal carcinoma in situ (n = 5) enhanced a mean of 59.6 HU +/- 2.8. Receiver operating characteristic curve analysis of lesion enhancement yielded an area under the receiver operating characteristic curve of 0.876.
Conspicuity of malignant breast lesions, including ductal carcinoma in situ, is significantly improved at contrast-enhanced breast CT. Quantifying lesion enhancement may aid in the detection and diagnosis of breast cancer.
定量分析专用乳腺 CT 扫描时乳腺病变的造影增强情况,并比较其与平扫乳腺 CT 和乳腺 X 线摄影的对比显示效果。
本研究符合 HIPAA 标准,经机构审查委员会和放射使用委员会批准,并获得书面知情同意。2006 年 9 月至 2009 年 4 月,46 例女性患者(平均年龄 53.2 岁,年龄 35-72 岁),乳腺影像报告和数据系统(BI-RADS)分类为 4 类或 5 类的病灶,在活检前行平扫乳腺 CT 和对比增强乳腺 CT。两位放射科医生独立评估增强乳腺 CT 与乳腺 X 线摄影、增强乳腺 CT 与平扫乳腺 CT 的病灶显示效果。使用手动分割图像,在测量病变的平均像素强度后,将其与脂肪组织强度进行归一化。回归模型重点分析了对比显示效果和造影增强情况,用于评估病理诊断(良性与恶性)、病变类型(肿块与钙化)、乳腺密度和两位放射科医生之间的差异。
46 例患者共 54 个病灶(25 个良性,29 个恶性)纳入研究。恶性病灶在增强乳腺 CT 上的显示效果明显优于平扫乳腺 CT(P<0.001)和乳腺 X 线摄影(P<0.001)。恶性钙化(仅在乳腺 X 线摄影上表现为微钙化的恶性病灶,n=7)在增强乳腺 CT 上的显示效果优于平扫乳腺 CT(P<0.001),与增强乳腺 CT 和乳腺 X 线摄影的显示效果相似。恶性病灶增强 55.9HU±4.0(标准误差),良性病灶增强 17.6HU±6.1(P<0.001)。导管原位癌(n=5)增强平均 59.6HU±2.8。病灶增强的受试者工作特征曲线分析得出曲线下面积为 0.876。
包括导管原位癌在内的乳腺恶性病变在增强乳腺 CT 上的显示效果明显改善。定量分析病灶增强程度可能有助于提高乳腺癌的检出和诊断。